IMpower133：期中分析达到共同主要终点（OS PFS）
实验设计：Atezo+卡铂+依托泊苷 vs 安慰剂卡铂+依托泊苷
定位一线治疗广泛期(ES)小细胞肺癌，大概找了几组数据，不一定准确。
小细胞肺癌SCLC占整个肺癌15-20%，这个大家比较清楚，目前没有发现明确的dirven gene和biomarker。
从分期的角度有数字分期的系统性分期，但从治疗的角度，很多医生都采用两期法：即局限期和广泛期。
局限期小细胞肺癌（LS-SCLC）：癌症仅在胸部的一侧并且可用单个辐射野进行治疗，也就是局限在足够小的区域，以便在一个“端口”中用放射治疗进行治疗。约1/3的首次发现SCLC患者为LS-SCLC。
广泛期小细胞肺癌（ES-SCLC）:广泛分布在一侧肺、另一侧肺、胸部另一侧淋巴结或身体其他部分（包括骨髓），另外扩散到肺周围流体的SCLC也是ES-SCLC。约2/3的首次发现SCLC患者为ES-SCLC。
药物治疗就是化疗了，这里不赘述。
当然还有K药、O药
想到这里，还是有点小激动。
最后感慨下，且看今日之域中，究竟是谁家之天下！
下面是正文，其实也没干货
Genentech, a member of the Roche Group announced that the Phase III IMpower 133 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis. The study demonstrated that initial (first-line) treatment with the combination of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and etoposide) helped people with extensive-stage small cell lung cancer (ES-SCLC) live significantly longer compared to chemotherapy alone. The Tecentriq-based combination also reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone. Safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. These data will be presented at an upcoming medical meeting.
These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer, a particularly difficult-to-treat type of disease. This is the fourth positive Phase III lung cancer study evaluating a Tecentriq-based combination to read out this year and the fifth positive study overall. Currently, Genentech has eight Phase III lung cancer studies underway evaluating Tecentriq alone or in combination with other medicines across different types of lung cancer.
About the IMpower 133 study: IMpower 133 is a Phase III, multicenter, double-blinded, randomized placebo-controlled study evaluating the efficacy and safety of Tecentriq in combination with carboplatin and etoposide versus chemotherapy (carboplatin plus etoposide) alone in chemotherapy-naïve people with ES-SCLC. The study enrolled 403 people who were randomized equally (1:1) to receive: Tecentriq in combination with carboplatin and etoposide (Arm A), or Placebo in combination with carboplatin and etoposide (Arm B, control arm) During the treatment-induction phase, people received treatment on 21-day cycles for four cycles, followed by maintenance with Tecentriq or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment could be continued until persistent radiographic PD or symptomatic deterioration was observed.The co-primary endpoints were: PFS as determined by the investigator using RECIST v1.1 in the intention-to-treat (ITT) population .OS in the ITT population IMpower 133 met its OS and PFS co-primary endpoints as per the study protocol.